• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降低细胞培养中的变异性。

Decreasing variability in your cell culture.

作者信息

Stein Aaron

机构信息

GIBCO Cell Culture Systems, Invitrogen.

出版信息

Biotechniques. 2007 Aug;43(2):228-9. doi: 10.2144/000112561.

DOI:10.2144/000112561
PMID:17824391
Abstract

Culturing mammalian cells has not significantly changed in almost 50 years. Typically, a synthetic basal medium is chosen to meet the environmental and nutritional requirements of a given cell line. Components, such as amino acids, vitamins, inorganic salts, and a carbon source such as glucose are commonly found in the classical basal media formulation. These basal formulations normally will not support cell growth alone, but must be further supplemented with animal serum, usually fetal bovine serum (FBS) at a concentration of 5-20%. Recent advances in serum-free and chemically defined media formulations have provided cell culturists with options. When considering FDA regulations and potential risks to human health when manufacturing biologics or considering cell therapies, eliminating serum is of paramount concern. For a large majority of researchers however, using classical media with serum builds on previous generations of research and makes cell culture easier to perform.

摘要

近50年来,哺乳动物细胞培养技术并没有显著变化。通常,会选择一种合成基础培养基来满足特定细胞系的环境和营养需求。经典基础培养基配方中常见的成分包括氨基酸、维生素、无机盐以及如葡萄糖这样的碳源。这些基础配方通常不能单独支持细胞生长,而是必须进一步添加动物血清,通常是浓度为5%-20%的胎牛血清(FBS)。无血清和化学成分确定的培养基配方的最新进展为细胞培养人员提供了更多选择。在考虑制造生物制品或细胞疗法时的FDA法规以及对人类健康的潜在风险时,去除血清是至关重要的。然而,对于绝大多数研究人员来说,使用含血清的经典培养基是基于前几代的研究,并且使细胞培养操作更简便。

相似文献

1
Decreasing variability in your cell culture.降低细胞培养中的变异性。
Biotechniques. 2007 Aug;43(2):228-9. doi: 10.2144/000112561.
2
Differences in the glycosylation profile of a monoclonal antibody produced by hybridomas cultured in serum-supplemented, serum-free or chemically defined media.在补充血清、无血清或化学成分确定的培养基中培养的杂交瘤产生的单克隆抗体的糖基化谱差异。
Biotechnol Appl Biochem. 2007 Jun;47(Pt 2):113-24. doi: 10.1042/BA20060216.
3
Goat serum: an alternative to fetal bovine serum in biomedical research.山羊血清:生物医学研究中胎牛血清的替代品。
Indian J Exp Biol. 2004 Jan;42(1):26-35.
4
Adaptation of Mammalian Cells to Chemically Defined Media.哺乳动物细胞对化学成分明确的培养基的适应性
Curr Protoc Toxicol. 2019 Dec;82(1):e88. doi: 10.1002/cptx.88.
5
Formulation of a basal medium for primary cell culture of the marine sponge Hymeniacidon perleve.用于海洋海绵珍珠拟海牛原代细胞培养的基础培养基的配方。
Biotechnol Prog. 2005 May-Jun;21(3):1008-12. doi: 10.1021/bp050029c.
6
Biochemical and functional characterization of heat-inactivated coelomic fluid from earthworms as a potential alternative for fetal bovine serum in animal cell culture.热灭活蚯蚓体腔液的生化和功能特征,作为动物细胞培养中胎牛血清的潜在替代品。
Sci Rep. 2024 Mar 7;14(1):5606. doi: 10.1038/s41598-024-56169-0.
7
Culture of transgenic Drosophila melanogaster Schneider 2 cells in serum-free media based on TC100 basal medium.基于TC100基础培养基在无血清培养基中培养转基因黑腹果蝇Schneider 2细胞。
Biotechnol J. 2007 Nov;2(11):1399-407. doi: 10.1002/biot.200700048.
8
Designing media for animal cell culture: CHO cells, the industrial standard.设计用于动物细胞培养的培养基:CHO细胞,行业标准。
Methods Mol Biol. 2014;1104:89-103. doi: 10.1007/978-1-62703-733-4_7.
9
Best practices for media selection for mammalian cells.哺乳动物细胞培养基选择的最佳实践。
In Vitro Cell Dev Biol Anim. 2017 Sep;53(8):673-681. doi: 10.1007/s11626-017-0186-6. Epub 2017 Jul 19.
10
Maximizing the relevance and reproducibility of A549 cell culture using FBS-free media.使用无胎牛血清培养基最大限度地提高 A549 细胞培养的相关性和可重复性。
Toxicol In Vitro. 2022 Sep;83:105423. doi: 10.1016/j.tiv.2022.105423. Epub 2022 Jun 24.

引用本文的文献

1
Longitudinal characterization of TK6 cells sequentially adapted to animal product-free, chemically defined culture medium: considerations for genotoxicity studies.对依次适应无动物产品、化学成分明确的培养基的TK6细胞进行纵向表征:遗传毒性研究的考量因素。
Front Toxicol. 2023 Jul 4;5:1177586. doi: 10.3389/ftox.2023.1177586. eCollection 2023.
2
Interlaboratory evaluation of a digital holographic microscopy-based assay for label-free in vitro cytotoxicity testing of polymeric nanocarriers.基于数字全息显微镜的无标记体外细胞毒性检测的聚合物纳米载体的实验室间评估。
Drug Deliv Transl Res. 2022 Sep;12(9):2207-2224. doi: 10.1007/s13346-022-01207-5. Epub 2022 Jul 8.
3
Standardization of an in vitro assay matrix to assess cytotoxicity of organic nanocarriers: a pilot interlaboratory comparison.
体外细胞毒性评估用基质的标准化:一项试点实验室间比较研究。
Drug Deliv Transl Res. 2022 Sep;12(9):2187-2206. doi: 10.1007/s13346-022-01203-9. Epub 2022 Jul 6.
4
Comparative analysis of mesenchymal stem cells cultivated in serum free media.无血清培养基中培养的间充质干细胞的比较分析。
Sci Rep. 2022 May 21;12(1):8620. doi: 10.1038/s41598-022-12467-z.
5
Induced pluripotent stem cell-based organ-on-a-chip as personalized drug screening tools: A focus on neurodegenerative disorders.基于诱导多能干细胞的芯片器官作为个性化药物筛选工具:聚焦神经退行性疾病
J Tissue Eng. 2022 May 9;13:20417314221095339. doi: 10.1177/20417314221095339. eCollection 2022 Jan-Dec.
6
Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility.整合多个生物学背景揭示了影响可重复性的合成致死性原则。
Nat Commun. 2020 May 12;11(1):2375. doi: 10.1038/s41467-020-16078-y.
7
Efficient isolation and proliferation of human adipose-derived mesenchymal stromal cells in xeno-free conditions.无血清/动物成分条件下高效分离和扩增人脂肪间充质基质细胞。
Mol Biol Rep. 2020 Apr;47(4):2475-2486. doi: 10.1007/s11033-020-05322-9. Epub 2020 Mar 2.
8
Clinical Trials of Limbal Stem Cell Deficiency Treated with Oral Mucosal Epithelial Cells.角膜缘干细胞缺乏症的口腔黏膜上皮细胞治疗的临床试验。
Int J Mol Sci. 2020 Jan 9;21(2):411. doi: 10.3390/ijms21020411.
9
Enhanced Cell Growth of Adipocyte-Derived Mesenchymal Stem Cells Using Chemically-Defined Serum-Free Media.使用化学成分明确的无血清培养基增强脂肪来源间充质干细胞的细胞生长
Int J Mol Sci. 2017 Aug 16;18(8):1779. doi: 10.3390/ijms18081779.
10
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.用于生产工程化自体嵌合抗原受体T细胞(CAR-T)疗法的快速细胞扩增过程。
Hum Gene Ther Methods. 2016 Dec;27(6):209-218. doi: 10.1089/hgtb.2016.120.